January 23, 2017 / 6:43 PM / 3 years ago

BRIEF-NantKwest says FDA authorized co's IND for early-stage study

Jan 23 (Reuters) - NantKwest Inc -

* NantKwest - U.S. FDA has authorized co’s IND for its first-in-human, high-affinity natural killer (haNK) cell therapy Phase I clinical study Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below